医学
细胞疗法
嵌合抗原受体
食品药品监督管理局
免疫疗法
免疫系统
肿瘤科
生物
癌症研究
免疫学
细胞
药理学
遗传学
作者
Ranjit Nair,Jason R. Westin
标识
DOI:10.1007/978-3-030-41008-7_10
摘要
CAR-T (chimeric antigens receptor-T) cell therapy is a breakthrough therapy of the twenty-first century for the management of different malignancies including lymphomas and leukemias. Numeral trials are underway to understand the optimal CAR-T cell design and dose to maximize efficacy and mitigate toxicity. Currently two CAR-T cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, are approved by the US Food and Drug Administration, which have shown excellent responses in otherwise poor prognostic lymphomas and leukemias. The favorable outcomes achieved of this therapy were noted to be durable during long-term follow-up. Understanding the challenges associated with manufacturing and the reasons for T cell failure including poor T cell expansion, persistence, and tumor resistance are critical for its wide-scale application in order to attain the full potential of this novel therapy. Here we review the salient features of the different CAR-T products and discuss the pivotal trials that led to its approval.
科研通智能强力驱动
Strongly Powered by AbleSci AI